ICLR vs. MEDP, INCY, CRL, EXAS, IQV, WST, ZBH, PHG, CAH, and ARGX
Should you be buying ICON Public stock or one of its competitors? The main competitors of ICON Public include Medpace (MEDP), Incyte (INCY), Charles River Laboratories International (CRL), Exact Sciences (EXAS), IQVIA (IQV), West Pharmaceutical Services (WST), Zimmer Biomet (ZBH), Koninklijke Philips (PHG), Cardinal Health (CAH), and argenx (ARGX). These companies are all part of the "medical" sector.
ICON Public (NASDAQ:ICLR) and Medpace (NASDAQ:MEDP) are both large-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their community ranking, valuation, media sentiment, dividends, analyst recommendations, risk, earnings, profitability and institutional ownership.
In the previous week, Medpace had 16 more articles in the media than ICON Public. MarketBeat recorded 20 mentions for Medpace and 4 mentions for ICON Public. ICON Public's average media sentiment score of 0.89 beat Medpace's score of 0.88 indicating that ICON Public is being referred to more favorably in the media.
ICON Public received 258 more outperform votes than Medpace when rated by MarketBeat users. Likewise, 64.99% of users gave ICON Public an outperform vote while only 64.00% of users gave Medpace an outperform vote.
ICON Public presently has a consensus price target of $339.44, suggesting a potential upside of 7.63%. Medpace has a consensus price target of $443.00, suggesting a potential upside of 13.53%. Given Medpace's higher probable upside, analysts clearly believe Medpace is more favorable than ICON Public.
95.6% of ICON Public shares are held by institutional investors. Comparatively, 78.0% of Medpace shares are held by institutional investors. 44.0% of ICON Public shares are held by insiders. Comparatively, 20.3% of Medpace shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.
ICON Public has a beta of 1.18, suggesting that its stock price is 18% more volatile than the S&P 500. Comparatively, Medpace has a beta of 1.4, suggesting that its stock price is 40% more volatile than the S&P 500.
Medpace has a net margin of 15.92% compared to ICON Public's net margin of 8.30%. Medpace's return on equity of 59.74% beat ICON Public's return on equity.
ICON Public has higher revenue and earnings than Medpace. ICON Public is trading at a lower price-to-earnings ratio than Medpace, indicating that it is currently the more affordable of the two stocks.
Summary
ICON Public and Medpace tied by winning 9 of the 18 factors compared between the two stocks.
Get ICON Public News Delivered to You Automatically
Sign up to receive the latest news and ratings for ICLR and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding ICLR and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
ICON Public Competitors List
Related Companies and Tools
